Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in severe pulmonary arterial hypertension
2009-012057-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Imatinib add-on with Placebo add-on (2 arms). Primary endpoint: Change in 6-minute walk distance. Started Jun 2009; status: completed.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2009-012057-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012057-38.